R. Burkes

668 total citations
18 papers, 405 citations indexed

About

R. Burkes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, R. Burkes has authored 18 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in R. Burkes's work include Lung Cancer Treatments and Mutations (10 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). R. Burkes is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). R. Burkes collaborates with scholars based in Canada, United States and Australia. R. Burkes's co-authors include Frances A. Shepherd, Ronald Feld, Lisa W. Le, Natasha B. Leighl, Geoffrey Liu, Jeffrey Tanguay, Suzanne Kamel‐Reid, D. Hwang, Gilda da Cunha Santos and Chétana Lim and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

R. Burkes

18 papers receiving 390 citations

Peers

Countries citing papers authored by R. Burkes

Since Specialization

Citations

This map shows the geographic impact of R. Burkes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Burkes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Burkes more than expected).

Fields of papers citing papers by R. Burkes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Burkes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Burkes. The network helps show where R. Burkes may publish in the future.

Co-authorship network of co-authors of R. Burkes

This figure shows the co-authorship network connecting the top 25 collaborators of R. Burkes. A scholar is included among the top collaborators of R. Burkes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Burkes. R. Burkes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Toronto Management of Initially Unresectable Liver Metastasis from Colorectal Cancer in a Living Donor Liver Transplant Program 2023 ·Journal of the American College of Surgeons ·Luckshi Rajendran, Marco P. A. W. Claasen, Ian D. McGilvray, Mark S. Cattral, Anand Ghanekar, Nazia Selzner, R. Burkes, Erin Winter, Steven Gallinger, Gonzalo Sapisochín	22
2	A Randomized Trial of the Electronic Lung Cancer Symptom Scale for Quality-of-Life Assessment in Patients with Advanced Non-small-Cell Lung Cancer 2020 ·Current Oncology ·James Kuo, Donna M. Graham, (unknown), (unknown), Lisa W. Le, Frances A. Shepherd, R. Burkes, Patricia J. Hollen, Richard J. Gralla, Natasha B. Leighl	6
3	P3.01-062 The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing 2017 ·Journal of Thoracic Oncology ·T. Barnes, Janessa Laskin, Parneet Cheema, (unknown), (unknown), J. Rothenstein, R. Burkes, Scott Owen, (unknown), (unknown), (unknown), Lindsay M. Wong, (unknown), (unknown), Ming‐Sound Tsao, N. B. Leighl	1
4	P3.01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing 2017 ·Journal of Thoracic Oncology ·Ming‐Sound Tsao, (unknown), Parneet Cheema, Janessa Laskin, Aly Karsan, T. Barnes, (unknown), Sarah Owen, J. Rothenstein, R. Burkes, (unknown), Alan Spatz, Iyare Izevbaye, Léon C.L.T. van Kempen, Suzanne Kamel‐Reid, N. B. Leighl	1
5	Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer 2015 ·Annals of Oncology ·Chétana Lim, Ming‐Sound Tsao, Lisa W. Le, Frances A. Shepherd, Ronald Feld, R. Burkes, Geoffrey Liu, Suzanne Kamel‐Reid, D. Hwang, Jeffrey Tanguay, Gilda da Cunha Santos, Natasha B. Leighl	179
6	Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17 2012 ·Annals of Oncology ·Michael M. Vickers, Christos S. Karapetis, Dongsheng Tu, Chris J. O’Callaghan, Timothy Price, Niall C. Tebbutt, Guy van Hazel, Jeremy Shapiro, Nick Pavlakis, Peter Gibbs, John Blondal, (unknown), J. Meharchand, R. Burkes, S. Rubin, John Simes, John Zalcberg, Malcolm J. Moore, Liting Zhu, Derek J. Jonker	38
7	The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. 2011 ·Journal of Clinical Oncology ·Michael M. Vickers, Christos S. Karapetis, Dongsheng Tu, Chris J. O’Callaghan, Timothy Price, Niall C. Tebbutt, Guy van Hazel, Jeremy Shapiro, Nick Pavlakis, Peter Gibbs, John Blondal, (unknown), J. Meharchand, R. Burkes, S. Rubin, John Simes, John Zalcberg, Malcolm J. Moore, Liting Zhu, Derek J. Jonker	5
8	6143 POSTER Study 20050203/PRIME – Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) 2011 ·European Journal of Cancer ·Salvatore Siena, Jean‐Yves Douillard, (unknown), Josep Tabernero, R. Burkes, Mario Barugel, Yves Humblet, David Cunningham, Hua Yu, Kartik Krishnan	1
9	Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). 2011 ·Journal of Clinical Oncology ·Jean‐Yves Douillard, Salvatore Siena, J Cassidy, Josep Tabernero, R. Burkes, Mario Barugel, Yves Humblet, David Cunningham, Feng Xu, Kartik Krishnan	17
10	Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS). 2011 ·Journal of Clinical Oncology ·Salvatore Siena, J Cassidy, Josep Tabernero, R. Burkes, Mario Barugel, Yves Humblet, David Cunningham, Feng Xu, Kartik Krishnan, Jean‐Yves Douillard	6
11	Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data 2008 ·Journal of Clinical Oncology ·Salvatore Siena, Josep Tabernero, R. Burkes, J Cassidy, David Cunningham, Mario Barugel, Yves Humblet, (unknown), Mona Shing, Jean‐Yves Douillard	24
12	Compliance of adjuvant chemotherapy in non-small cell lung cancer (NSCLC); No longer an issue 2006 ·Journal of Clinical Oncology ·(unknown), Natasha B. Leighl, Melania Pintilie, R. Feld, R. Burkes, Frances A. Shepherd	1
13	O-63 Brain metastases as the initial site of failure in locally advanced non-small cell lung cancer treated with combined modality therapy: Implications for prophylactic cranial irradiation 2003 ·Lung Cancer ·A. Sun, Hannah Carolan, Andrea Bezjak, Qilong Yi, (unknown), Robert J. Ginsberg, Gabrielle Kane, John Waldron, Natasha B. Leighl, Ron Feld, R. Burkes, David G. Payne	2
14	Single agent Gemcitabine for elderly patients with non small cell lung cancer (NSCLC): A phase II study 2000 ·Lung Cancer ·R. Burkes, (unknown), Frances A. Shepherd, Silvana Spadafora, J. Iglesias	4
15	Epiphora in patients receiving systemic 5-fluorouracil therapy. 1998 ·PubMed ·(unknown), J. J. Hurwitz, R. Burkes	12
16	Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. 1997 ·PubMed ·Frances A. Shepherd, Yvon Cormier, R. Burkes, William K. Evans, Geraldine Goss, Paul Klimo, R. Feld, Michael D. Taylor	55
17	Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose. 1996 ·Journal of Clinical Oncology ·Frances A. Shepherd, R. Burkes, Yvon Cormier, M. Crump, Ronald Feld, (unknown), (unknown)	25
18	Scintigraphic Flare in Skeletal Lymphoma 1994 ·Clinical Nuclear Medicine ·Lawrence M. White, Bruce Gray, Masanori Ichise, Joel C. Kirsh, R. Burkes	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact